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Infections of cell cultures. Virus was added to cells at a multiplicity of infection (MOI) of 1 PFU/cell 171 and allowed to adsorb for 1 hour at 37 °C. Cultures were washed with PBS (3 times) and fed with 172 medium as described for each cell type. The culture supernatants were harvested at the times 173 indicated for the specific experiments, and the titers were determined by plaque assay on L2 cells. 
184
Bioassay for antiviral activity. Supernatants recovered from cells that were infected with MHV 185 strains at an MOI of 1 PFU/cell were exposed to 600 mJoules•cm -2 UVA light in a Stratalinker 1800 186 (Stratagene) to inactivate the virus. L2 mouse fibroblasts were treated with the UV-inactivated 187 supernatants for 24 hours and then infected with NDV-GFP at an MOI of 1 PFU/cell as described 
200
infected cells was isolated using an RNeasy kit (Qiagen) and quantified using a Nanodrop analyzer.
201
Equal amounts of RNA were separated on RNA chips and analyzed with an Agilent 2100
202
Bioanalyzer (Agilent Technologies) as described previously (25, 44) . RNA integrity numbers (referred 203 to as RIN values) (45) a measurement of RNA integrity produced by the bioanalyzer are also 204 indicated.
206
Immunoblotting. Cells were treated with 0 or 100 units/mL of universal IFNα, for four hours and 207 then lysed in nonidet P-40 (NP-40) buffer (1% NP-40, 2 mM EDTA, 10% glycerol, 150 mM NaCl and 208 50 mM Tris pH 8.0) containing protease inhibitors (Roche). Protein concentrations were measured 209 using a DC protein assay kit (Bio-Rad). Supernatants were mixed 1:1 with 2X SDS-PAGE sample 210 buffer. Samples were boiled, separated by 10% SDS-PAGE and transferred to polyvinylidene 211 difluoride (PVDF) membranes. Blots were blocked with 5% nonfat milk and probed with the following 212 antibodies directed against: OAS1A (clone E-2, Santa Cruz; 1:200), OAS2 (clone G-9, Santa Cruz, 
234
Fluorescence intensity, dependent on both surface IFNAR1 density and cell surface area, 235 was normalized by cell size using previously described methods (47). This allowed us to compare 236 receptor density between cells of different sizes. Briefly, forward scatter (FSC), a measure of cell 
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Activation of RNase L during ns2 H126R infection of dendritic cells correlates with high basal 250
Oas gene expression
251
We showed previously that while A59 antagonizes the OAS-RNase L pathway in myeloid 252 lineage cells, including brain-resident microglia and liver-resident Kupffer cells as well as bone 253 marrow derived macrophages (BMM) (2,25,29,34), ns2 H126R , a mutant expressing an inactive 254 phosphodiesterase (PDE) fails to antagonize RNase L and consequently has severely restricted 255 replication in these cell types. In contrast, replication of ns2 H126R in primary cell types including 256 neurons, astrocytes, and hepatocytes as well as in immortalized cell lines was as robust as A59
257
(2,25,29). We investigated whether other myeloid cells, such as dendritic cells, would behave 258 similarly to macrophages upon infection. Thus, we compared the replication of A59 and ns2 H126R in 259 BMM and bone marrow derived dendritic cells (BMDC), derived from B6 (WT) mice. As observed in 260 BMM ( Figure 2A ) (25,29), BMDC ( Figure 2B ) also restricted mutant virus replication by 100 fold at 261 12 hours (p<0.01) and 1000 fold after 24 hours post infection (p<0.001).
262
We next compared the basal level of expression of Oas genes in BMDC with those of BMM 263 and neurons. Using real-time quantitative RT-PCR, we quantified basal levels of expression of three
264
Oas genes that encode catalytically active OAS proteins, Oas1a, Oas2, and Oas3, in WT BMM and 265 WT BMDC cultures in comparison to primary neurons ( Figure 2C ), the latter shown previously to 266 express minimal basal levels of OAS genes and to be unable to restrict replication of ns2 H126R (29).
267
Oas mRNA expression levels in neurons, as expected, were under the limit of detection and in 268 comparison basal mRNA expression levels of Oas1a, Oas2, and Oas3 genes in WT BMM and WT 12 BMDC were 1000 fold greater than the minimal detectable level ( Figure 2C ). Levels of OAS1A,
270
OAS2, OAS3 and RNase L were similar in BMM and BMDC culture, as assessed by immunoblotting 271 ( Figure 2D ). In order to compare RNase L activation during A59 and ns2 H126R infection, we monitored 272 the state of ribosomal RNA (rRNA) cleavage in WT BMM and BMDC infected with either ns2 H126R or 273 A59. The mutant virus ns2 H126R induced rRNA cleavage at 9 and 12 hours post infection in BMM and 274 BMDC ( Figure 2E ). In contrast, A59 did not induce rRNA cleavage, similar to mock infected cells, 
282
We investigated whether the level of RNase L expression contributes to the differences 283 observed between activation of RNase L and ns2 H126R replication in myeloid and non-myeloid cells.
284
Thus, we compared BMM and astrocytes, the latter previously shown to express low levels of Oas 285 genes as compared with BMM (29). We quantified Rnasel protein levels by Western blot in BMM 286 and astrocytes using cells derived from Rnasel -/mice as a negative control. RNase L protein 287 expression levels were similar in BMM and astrocytes ( Figure 3A ).
288
As RNase L activation is dependent on the production of 2-5A, we investigated whether Figure 4B ), while Ifih1 -/-BMM cultures did not produce detectable 318 IFNβ. Replication of ns2 H126R was 100 fold reduced at 12 hpi and 1000 fold attenuated after 24 hours 319 14 in Ifih1 -/macrophages ( Figure 4D ) compared to A59 in WT BMM ( Figure 4C ) (25) indicating that 320 ns2 H126R replication is restricted in BMM even in the absence of virus-induced IFN production.
321
Consistent with the above findings, we observed similar levels of Oas and Rnasel mRNA in 322 WT and Ifih1 -/-BMM ( Figure 4E ). In addition, the corresponding protein levels of OAS1A, OAS2,
323
OAS3 and RNase L appeared to be at least as high in Ifih1 -/-BMM as in WT BMM ( Figure 4F ). While 324 these immunoblot data show a small to modest increase in OAS1A, OAS2, OAS3 and RNase L 325 levels in Ifih1 -/cells compared to WT, other replicates failed to show any detectable differences 326 (data not shown). Furthermore, we compared the levels of other ISGs in WT and Ifih1 -/-BMM and 327 found little difference in their relative mRNA expression levels, with the exception of MDA5, which as 328 expected was not expressed in Ifih1 -/-BMM cultures ( Figure 4G ). Finally, RNase L activation was 329 observed in both genotypes of BMM by 12 hours post infection with ns2 H126R while it was also 330 evident at 9 hours in WT cells. Thus, infection with ns2 H126R activated RNase L in the absence of 
337
Indeed, we have reported much higher levels of ISG expression in myeloid cells that are able to 338 induce IFN and activate RNase L during MHV infection, as compared to other cell types (2, 29) . As in 339 the data shown above ( Figure 4C ), ns2 H126R was preferentially restricted compared to A59 in WT 340 BMM starting at 9 hours and 100-1000 fold decreased from 12 to 24 hours after infection ( Figure   341 5A). However, replication of ns2 H126R was fully recovered in Ifnar1 -/-BMM ( Figure 5B ).
342
We compared the expression of several Oas genes in WT and Ifnar1 -/-BMM and found 343 reduced expression of Oas1a (p<0.01), Oas2 (p<0.001), and Oas3 (p<0.01) mRNAs in Ifnar1 -/-344 BMM, presumably due to loss of basal IFN signaling, but no significant difference in Rnasel mRNA 345 15 expression ( Figure 5C ). Furthermore, we compared the basal protein expression levels of OAS1A,
346
OAS2, and RNase L in BMM derived from WT or Ifnar1 -/mice. OAS1A, OAS2 and OAS3 protein 347 was undetectable in cell lysates from Ifnar1 -/-BMM cultures ( Figure 5D ) with or without prior IFN 
359
We hypothesized that the difference in basal ISG expression between macrophages and 360 astrocytes could be at least in part due to the cell surface expression level of type I interferon 361 receptor, IFNAR1. Cells with higher IFNAR1 surface expression might promote higher basal IFN 362 signaling and ISG levels and therefore be more likely to activate RNase L in the presence of dsRNA 363 early during ns2 H126R infection. To assess surface IFNAR1 expression on BMM, microglia and 364 astrocytes, BMM and primary astrocyte/microglia cultures were stained for identifying markers and 365 IFNAR1 and then analyzed by flow cytometry. As astrocytes displayed a larger range in size as 366 compared to macrophages (data not shown), we applied a size normalization algorithm to determine 367 density of surface IFNAR1. Using previously described methods (47) 
381
Following one hour of 2 µg/mL antibody pretreatment of WT BMM, there was no increase in Oas1,
382
Oas2 or Oas3 mRNA expression following infection, and the basal levels of mRNAs in mock infected 383 cells were the same as in "no mAb" controls ( Figure 6A-C) . Other ISGs, for example Ifit1, also failed 384 to be induced following infection (data not shown). Under these conditions, RNase L activity was still 385 activated by infection with ns2 H126R at 9 and 12 hours post infection ( Figure 6G ) resulting in 386 restriction of viral replication ( Figure 6E ). Thus, with a one hour pretreatment with 2 µg/mL of 387 antibody, basal mRNA levels of OAS genes are maintained and BMM retain the ability to restrict 388 MHV and activate RNase L, in the absence of upregulation of Oas expression levels. However, the 389 use of a higher dose of antibody (5 µg/mL) recapitulated the phenotype observed in Ifnar1 -/-BMM in 390 that basal levels of Oas mRNA expression in mock infected mice were decreased approximately 10 391 fold ( Figure 6A -C; compare mock infected, 5 µg/mL mAb treated to mock infected, no mAb 392 treatment). In addition, Oas mRNA levels were not induced by infection and activation of RNase L 393 did not occur as assessed by an rRNA degradation assay ( Figure 6G ) and replication of ns2 H126R 394 was no longer restricted ( Figure 6F ). It is important to note that treatment of cells with an isotype control antibody had no effect on replication of A59 or ns2 H126R and that the replication of ns2 H126R 396 was restricted following treatment with isotype control antibody ( Figure 6F 
